RT Journal Article SR Electronic T1 Clinical application of oxaliplatin in epithelial ovarian cancer JF International Journal of Gynecologic Cancer JO Int J Gynecol Cancer FD BMJ Publishing Group Ltd SP 1717 OP 1732 DO 10.1136/ijgc-00009577-200609000-00001 VO 16 IS 5 A1 S. Fu A1 J. J. Kavanagh A1 W. Hu A1 R. C. Bast YR 2006 UL http://ijgc.bmj.com/content/16/5/1717.abstract AB Platinum remains the most active drug class in ovarian cancer treatment; however, new single-agent and combination therapies are needed to improve the clinical outcome of ovarian cancer therapies. Oxaliplatin, a third-generation platinum derivative, has shown effective antitumor activity and a favorable toxicity profile in epithelial ovarian cancer. Preclinical evidence of the synergistic cytotoxic effect of oxaliplatin in combination with several other chemotherapeutic agents and clinical evidence of the absence of any dose-limiting hematologic toxicity associated with this agent have made oxaliplatin an attractive compound for combination agent therapy. This article reviews the current status of the clinical application of oxaliplatin alone and in a combination regimen in epithelial ovarian cancer treatment.